Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review

BACKGROUND: Trastuzumab (H) and pertuzumab (P) plus chemotherapy is the standard guideline-recommended neoadjuvant therapy recommended for patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced breast cancer (BC), which has dramatically improved patient prognosis. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Mei, Zhou, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005987/
https://www.ncbi.nlm.nih.gov/pubmed/36915810
http://dx.doi.org/10.21037/gs-22-751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005987/
https://www.ncbi.nlm.nih.gov/pubmed/36915810
http://dx.doi.org/10.21037/gs-22-751

Ejemplares similares